Emergency BU Alert BU Medical Campus OPEN Jan. 28, 2015 Boston University Medical Campus will be open Wednesday, Jan. 28, 2015. BUSM classes will be held as scheduled. Staff should check with their managers regarding work schedules. Medical, PA and GMS students who are assigned to inpatient services or clinics are expected to be present, if possible. Students who are assigned to outpatient services should check with their course director or the policy at the clinical site. GMS classes are canceled. Staff should check with their manager regarding their work schedules. The Henry M. Goldman School of Dental Medicine will follow normal school hours. All Patient Treatment Centers will be open for patient care and all classes will be held as scheduled. BU School of Public Health classes are canceled; SPH non-essential staff may telecommute. Employees who are part of the BUMC parking program should park in your assigned lot or garage. The Boston parking ban is still in effect. For updated information, please call the weather/emergency hotline at 617-638-6886 or visit the BU Emergency Communications website at http://www.bu.edu/ehs/comm/

STEADY PD (Safety, Tolerability, and Efficacy Assessment of Dynacirc® CR for PD)

Enrollment for this study is complete.

The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University), and Kevin Biglan, MD, MPH (University of Rochester), is conducting a multi-center, randomized, double-blind, placebo-controlled study of isradipine CR (Dynacirc® CR) in individuals with early Parkinson disease (PD) The purpose of the study is to assess the general safety and tolerability of isradipine CR, to determine effective dosage of isradipine CR and obtain pilot data on the potential effect of isradipine on slowing the progression of PD. Approximately 18 research centers across North America will enroll up to 100 subjects for 12 months each.

Isradipine CR is a medication that is approved for the treatment of high blood pressure by the Food and Drug Administration Agency (FDA), but not for the treatment of PD. Isradipine CR has been shown to have a neuroprotective effect in preclinical models of parkinsonism (poster Simuni, et al – see ref).

This study is being conducted under a research grant award from the Michael J. Fox Foundation (MJFF) and the Dixon Foundation.

For more information please contact Boston University Parkinson’s Disease and Movement Disorder Center at 617-638-7737.

IRB H-28533

August 22, 2012
Primary teaching affiliate
of BU School of Medicine